On November 7th, 2019, TrialSite News attended the Utah Life Sciences Summit. To say it was a success is an understatement. The amount of information gained, the highlighting speakers and experts from all over the clinical trial and pharmaceutical industry, made it a...
Biotechnology
Category
California’s Central Valley Center of German-Originated $28M Biotechnology Firm Investment
Visalia, California, traditionally known as the center of California’s agricultural belt, becomes more and more high-tech by the year. Most recently, MilliporeSigma announced the construction of a 120,000-square foot distribution center in the Visalia Industrial Park....
XenCor Doses First Patient in Phase I Study of Therapy for Treatment of Advanced Solid Tumors
Publicly traded biotech venture Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases. They announced that the first patient has been dosed in...
Hong Kong Greater Bay Area Boosting Biotech Presence
The South China Morning Post reports that the central government recently chartered a blueprint for the development of Greater Bay Area (GBA) that will economically integrate Hong Kong, Macau, Guangzhou, Shenzhen and neighboring cities to maximize economic synergies...
Cancer Developer Y-mABS Raises $96 Million in IPO
As reported in Xconomy, Frank Vinluan writes that cancer drug developer Y-mAbs Therapeutics is the latest biotech company to go public, raising $96 million in its IPO. New York-based Y-mAbs priced its offering of 6 million shares at $16 each, which was the high end of...
Memorial Sloan Kettering owns 8.45% of Biotech Venture Y-mAbs
Seeking Alpha writes about the potential benefits to MSK owning stake in new venture.
Sutro Biopharma Files for $75 Million IPO for Cancer and Autoimmune Therapies
Equities.com reports traditional drug discovery involves a resource and labor-intensive protein synthesis process that relies on cell-based design, production and manufacturing technologies. Specific DNA strands are incubated inside cells originating from bacteria,...
Immunomedics Partners with Multiple Clinical and Preclinical Collaborations with Prominent Research Centers
Immunomedics, a leading company focused on antibody-drug conjugates (ADC) announces a major collaboration with Yale Cancer Center to evaluate their lead ADC product candidate, sacituzumab govitecan, a single agent in two Phase II studies in patients with persistent or...
Kuopio Center: Innovative Gene and Cell Therapy Research Site
The Kuopio Center for Gene and Cell Therapy (KCT) is a newly established research center in Kuopio Finland with a focus on the development of novel gene and cell therapy products in the advanced therapy medicinal products (ATMPs) class. According to a recent article...
National Cancer Institute Improving Access to Clinical Trial Data and Specimens
The NCTN Navigator inventory contains data from nearly 100 trials, more than 50,000 patients and more than 850,000 specimens. See Navigator web site: https://navigator.ctsu.org/navigator/login Grace Mishkin, MPH, Public Health Analyst with NCI was interviewed by...
What Motivates Patients to Participate in Mitochondrial Disease Clinical Trials
As reported in Science Daily, Dr. Marni J. Falk, MD of executive director of the Mitochondrial Medicine Frontier Program at Children's Hospital of Philadelphia (CHOP) and study lead reports that "The inherent complexity of mitochondrial disease gave rise to our...